In addition to the direct impact of PI3K inhibition on breast cancer cell, inhibition of PI3K isoforms may restore the anti-tumor immune response and improve responsiveness to checkpoint blockade treatment, which may be a promising immunotherapy target for breast cancers. This evidence concerns the gene PIK3CB and neoplasm.